Premium
Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study ( MRISC )
Author(s) -
Saadatmand Sepideh,
Obdeijn IngeMarie,
Rutgers Emiel J.,
Oosterwijk Jan C.,
Tollenaar Rob A.,
Woldringh Gwendolyn H.,
Bergers Elisabeth,
Verhoef Cornelis,
Heijnsdijk Eveline A.,
Hooning Maartje J.,
de Koning Harry J.,
TilanusLinthorst Madeleine M.
Publication year - 2015
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.29534
Subject(s) - medicine , breast cancer , oncology , mammography , chemotherapy , cancer , gynecology , gastroenterology
Adding MRI to annual mammography screening improves early breast cancer detection in women with familial risk or BRCA1/2 mutation, but breast cancer specific metastasis free survival (MFS) remains unknown. We compared MFS of patients from the largest prospective MRI Screening Study (MRISC) with 1:1 matched controls. Controls, unscreened if<50 years, and screened with biennial mammography if ≥50 years, were matched on risk category ( BRCA1 , BRCA2 , familial risk), year and age of diagnosis. Of 2,308 MRISC participants, breast cancer was detected in 93 (97 breast cancers), who received MRI <2 years before breast cancer diagnosis; 33 BRCA1 mutation carriers, 18 BRCA2 mutation carriers, and 42 with familial risk. MRISC patients had smaller (87% vs . 52%